modelG02BB02
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | VaginalRingWithProgestogen | |
| ATC code: | G02BB02 | route: | intravaginal |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 3 | L |
| clearance: | 0.5 | L/h/kg |
| other parameters in model implementation | ||
Vaginal ring with progestogen is a contraceptive device designed for intravaginal administration of progestogen hormones to provide birth control. The drug is generally used for hormonal contraception and may also be indicated in hormone replacement therapy for some indications. Products with this ATC code (G02BB02) are used in approved medical practice in several countries.
Pharmacokinetics
Estimated pharmacokinetic parameters for general adult female users, as no specific referenced publication for PK parameters of vaginal programmable progestogen-only ring exists.
References
Brache, V, et al., & Lähteenmäki, P (2000). Progestin-only contraceptive rings. Steroids 65(10-11) 687–691. DOI:10.1016/s0039-128x(00)00175-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11108877
Nelson, AL (2019). Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method. Expert review of clinical pharmacology 12(10) 953–963. DOI:10.1080/17512433.2019.1669448 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31526281
Thakur, K, et al., & Polak, S (2024). Development and verification of mechanistic vaginal absorption and metabolism model to predict systemic exposure after vaginal ring and gel application. British journal of clinical pharmacology 90(6) 1428–1449. DOI:10.1111/bcp.16029 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38450818
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)